|1.||Chatterjee, Subroto: 3 articles (06/2014 - 01/2013)|
|2.||Mishra, Sumita: 2 articles (06/2014 - 06/2014)|
|3.||Haughey, Norman J: 2 articles (01/2013 - 01/2013)|
|4.||Sato, Ikuro: 2 articles (04/2009 - 08/2002)|
|5.||Yamaguchi, Kazunori: 2 articles (04/2009 - 08/2002)|
|6.||Miyagi, Taeko: 2 articles (04/2009 - 08/2002)|
|7.||Hussain, M Mahmood: 1 article (10/2015)|
|8.||Davidson, Nicholas O: 1 article (10/2015)|
|9.||Klein, Richard L: 1 article (10/2015)|
|10.||Cuchel, Marina: 1 article (10/2015)|
|1.||Lewis Lung Carcinoma
03/01/2003 - "Sialylation and sulfation of lactosylceramide distinctly regulate anchorage-independent growth, apoptosis, and gene expression in 3LL Lewis lung carcinoma cells."
07/20/2001 - "Suppression of integrin expression and tumorigenicity by sulfation of lactosylceramide in 3LL Lewis lung carcinoma cells."
03/01/2003 - "To investigate the significance of sialylation and sulfation of lactosylceramide in transformed cells, we established ganglioside GM3- and lactosylsulfatide (SM3)-reconstituted cells by transfecting cDNAs of GM3 synthase and cerebroside sulfotransferase into the J5 subclone of 3LL Lewis lung carcinoma cells. "
10/15/1990 - "Treatment of Lewis lung carcinoma cells with 5 microM D-PDMP resulted in a time-dependent marked decrease in levels of all cellular GSLs (glucosylceramide, lactosylceramide, ceramide trihexoside, globoside, and ganglioside GM3). "
|2.||Globoid Cell Leukodystrophy (Krabbe Disease)
07/31/1985 - "Galactosylceramide- and lactosylceramide-loading studies in cultured fibroblasts from normal individuals and patients with globoid cell leukodystrophy (Krabbe's disease) and GM1-gangliosidosis."
08/11/1980 - "With either galactosylceramide or lactosylceramide as substrate, and with phosphatidylserine as the activator, diagnosis of globoid cell leukodystrophy was possible using whole homogenates of cultured fibroblasts. "
02/28/1980 - "The data suggest that diagnoses of Krabbe's disease should be performed with galactosylceramide rather than lactosylceramide as substrate."
01/01/1976 - "Studies on the pathogenesis of Krabbe's leukodystrophy: cellular reaction of the brain to exogenous galactosylsphingosine, monogalactosyl diglyceride, and lactosylceramide."
10/01/1978 - "Metabolism of tritium-labelled galactosylceramide and lactosylceramide added to the culture medium was examined in cultured skin fibroblasts from 4 patients with globoid cell leukodystrophy (GLD) and 4 control individuals. "
|3.||GM1 Gangliosidosis (Gangliosidosis GM1)
07/15/1992 - "Lactosylceramide-loading studies confirmed that there was a defect in the turnover of this lipid in fibroblasts from the affected patient and fetus but not from a patient with an isolated SAP-1 deficiency, or from patients with Krabbe disease, GM1 gangliosidosis or galactosialidosis. "
03/01/1977 - "Diseases which can be incorporated into the scheme include Niemann-Pick disease, Gaucher disease, metachromatic leukodystrophy, Krabbe disease, ceramide lactoside lipidosis, Tay-Sachs disease, generalized gangliosidosis, Fabry disease, and Sandhoff disease. "
|4.||Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
|5.||Body Weight (Weight, Body)
03/01/2000 - "Glucosylceramide (GluCer), lactosylceramide (LacCer) and ganglioside G(D3) were fed individually to DMH-treated (six doses of 30 mg/kg body weight) female CF1 mice at 0.025 or 0.1 g/100 g of the diet for 4 wk. All reduced the number of ACF by > 40% (P < 0.001), which is comparable to the reduction by SM in earlier studies. "
|2.||RV 538 (PDMP)
|6.||Neuraminidase deficiency with beta-galactosidase deficiency
|1.||Heterologous Transplantation (Xenotransplantation)